- Home
- OPBK vs NVCT Comparison
OPBK vs NVCT Comparison
Compare OPBK & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPBK
- NVCT
- Stock Information
- Founded
- OPBK 2005
- NVCT 2020
- Country
- OPBK United States
- NVCT United States
- Employees
- OPBK N/A
- NVCT N/A
- Industry
- OPBK Major Banks
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- OPBK Finance
- NVCT Health Care
- Exchange
- OPBK Nasdaq
- NVCT Nasdaq
- Market Cap
- OPBK 196.5M
- NVCT 167.0M
- IPO Year
- OPBK 2018
- NVCT 2022
- Fundamental
- Price
- OPBK $13.10
- NVCT $6.03
- Analyst Decision
- OPBK Buy
- NVCT Strong Buy
- Analyst Count
- OPBK 2
- NVCT 3
- Target Price
- OPBK $16.50
- NVCT $15.33
- AVG Volume (30 Days)
- OPBK 39.7K
- NVCT 109.6K
- Earning Date
- OPBK 10-23-2025
- NVCT 11-04-2025
- Dividend Yield
- OPBK 3.66%
- NVCT N/A
- EPS Growth
- OPBK 13.19
- NVCT N/A
- EPS
- OPBK 1.58
- NVCT N/A
- Revenue
- OPBK $87,081,000.00
- NVCT N/A
- Revenue This Year
- OPBK $22.24
- NVCT N/A
- Revenue Next Year
- OPBK $10.31
- NVCT N/A
- P/E Ratio
- OPBK $8.30
- NVCT N/A
- Revenue Growth
- OPBK 10.57
- NVCT N/A
- 52 Week Low
- OPBK $10.43
- NVCT $4.44
- 52 Week High
- OPBK $18.57
- NVCT $11.52
- Technical
- Relative Strength Index (RSI)
- OPBK 46.87
- NVCT 49.43
- Support Level
- OPBK $12.63
- NVCT $5.86
- Resistance Level
- OPBK $13.31
- NVCT $6.24
- Average True Range (ATR)
- OPBK 0.26
- NVCT 0.33
- MACD
- OPBK -0.03
- NVCT -0.00
- Stochastic Oscillator
- OPBK 49.84
- NVCT 61.76
About OPBK OP Bancorp
OP Bancorp is engaged in the general commercial banking business in Los Angeles, Orange, and Santa Clara Counties, California, Carrollton, Texas, and Las Vegas, Nevada. The Bank is focused on serving the banking needs of small- and medium-sized businesses, professionals, and residents with a particular emphasis on Korean and other ethnic minority communities. It operates with eleven full branches.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.